|
|
|
Volumn 23, Issue 1, 2008, Pages 1-4
|
|
CYP2D6 pharmacogenomics of tamoxifen treatment.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
CYTOCHROME P450;
CYTOCHROME P450 2D6;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TAMOXIFEN;
ADJUVANT CHEMOTHERAPY;
ARTICLE;
BREAST TUMOR;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
GENETICS;
GENOTYPE;
HUMAN;
METABOLISM;
OUTCOME ASSESSMENT;
PAGET NIPPLE DISEASE;
PATIENT SELECTION;
PHARMACOGENETICS;
POSTMENOPAUSE;
SAFETY;
SENSITIVITY AND SPECIFICITY;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
UNITED STATES;
ANTINEOPLASTIC AGENTS, HORMONAL;
BREAST NEOPLASMS;
CARCINOMA, DUCTAL, BREAST;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS AS TOPIC;
CYTOCHROME P-450 CYP2D6;
CYTOCHROME P-450 ENZYME SYSTEM;
DEVICE APPROVAL;
DISEASE-FREE SURVIVAL;
FEMALE;
GENOTYPE;
HUMANS;
NEOPLASM RECURRENCE, LOCAL;
OUTCOME ASSESSMENT (HEALTH CARE);
PATIENT SELECTION;
PHARMACOGENETICS;
POSTMENOPAUSE;
SELECTIVE ESTROGEN RECEPTOR MODULATORS;
SENSITIVITY AND SPECIFICITY;
TAMOXIFEN;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 48249140204
PISSN: None
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|